Clinical Trials
19
Active:8
Completed:8
Trial Phases
3 Phases
Phase 1:7
Phase 2:4
Phase 3:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (38.9%)Phase 3
7 (38.9%)Phase 2
4 (22.2%)A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Phase 3
Completed
- Conditions
- Multiple SclerosisWalking Impairment
- Interventions
- Drug: ADS-5102, 274 mg
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 424
- Registration Number
- NCT03567057
- Locations
- 🇨🇦
Adamas Clinical Site, Québec City, Quebec, Canada
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
Phase 3
Completed
- Conditions
- Walking ImpairmentMultiple Sclerosis
- Interventions
- Drug: ADS-5102, 137 mgOther: PlaceboDrug: ADS-5102, 274 mg
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 558
- Registration Number
- NCT03436199
- Locations
- 🇨🇦
Adamas Clinical Site, Quebec City, Quebec, Canada
🇺🇸Admas Clinical Site, Detroit, Michigan, United States
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Phase 2
Completed
- Conditions
- Walking ImpairmentMultiple Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02471222
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Phase 3
Completed
- Conditions
- DyskinesiaLevodopa-Induced Dyskinesia (LID)Parkinson's Disease (PD)
- Interventions
- Other: Placebo
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT02274766
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Phase 3
Completed
- Conditions
- Levodopa Induced Dyskinesia (LID)Parkinson's Disease (PD)Dyskinesia
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT02202551
- Prev
- 1
- 2
- Next
News
No news found